Durvalumab‐induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non‐small cell lung cancer: A case report

Durvalumab is a humanized monoclonal antibody targeting programmed cell death ligand‐1 (PD‐L1), leading to an antitumor activity, used as consolidation therapy in patients with locally advanced unresectable non‐small cell lung cancer (NSCLC). Several immune‐related adverse events (irAEs) have previo...

Descripción completa

Detalles Bibliográficos
Autores principales: Domblides, Maël, Geier, Margaux, Decroisette, Chantal, Descourt, Renaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046106/
https://www.ncbi.nlm.nih.gov/pubmed/33624409
http://dx.doi.org/10.1111/1759-7714.13862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046106/
https://www.ncbi.nlm.nih.gov/pubmed/33624409
http://dx.doi.org/10.1111/1759-7714.13862

Ejemplares similares